A room temperature, cold, sporicide/sterilant with the rapid kill demonstrated by Ygiene(TM) Hospital Grade will provide a huge economic advantage for future users. By delivering a safe easy to use and a much quicker turn around time for total sterilization of equipment and facilities, BioNeutrals Ygiene(TM) will greatly reduce the waste of human resources and capital currently experienced in health care facilities and will maximize value to the user & increased safety for the patients.
Dr. Andy Kielbania PhD, Chief Scientist at BioNeutral Group stated: "These independent lab validation results from ATS show that we have developed what we believe is the best, and I emphasize the best, antimicrobial coming to the market. By using the strategy of raising the bar for antimicrobial performance, we believe our superior Ygiene(TM) Hospital Grade antimicrobial will provide much cleaner, safer and healthier environments in health care facilities globally. Reducing the loss of lives and wasteful expenditures of human resources and money by diminishing Hospital Acquired Infections (ACI) is our goal. These independent test results stand by themselves and are consistent with our achieving our goals and objectives. These results are incredible and validate all of our efforts."
Dr. Philip M. Tierno Jr. MS, PhD Chairman of BioNeutral Group Scientific Advisory Board stated: "The sporocidal data on Ygiene(TM)'s performance that I reviewed is quite impressive. Two immediate and important applications of Ygiene(TM) come to mind:
1- Perhaps the biggest challenge facing hospitals worldwide is eradication of Clostridium difficile spores in the environment in a timely fashion thereby reducing or eliminating possible nosocomial spread. Ygiene(TM) safely and e
|SOURCE BioNeutral Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved